Tom Unterman, Managing Partner, Rustic Canyon Partners

Tom Unterman is the managing partner and founder of Rustic Canyon Partners. Prior to Rustic Canyon, Tom had a long career as a corporate executive at Times Mirror Company and prior to that, a corporate lawyer at Morrison & Foerster LLP and Orrick, Herrington & Sutcliffe LLP. He earned his bachelor’s degree from Princeton University before receiving his law degree from the University of Chicago. In addition to Rustic Canyon portfolio companies, Tom currently serves on the boards of the California Community Foundation, The Los Angeles Museum of Contemporary Art, The Public Library of Science, Heal the Bay and The California Institute for the Arts and he is a member of the State of California Commission on Access to Justice.

David Travers, Principal, Rustic Canyon Partners

David brings technology, media, and national security experience to Navigating Cancer’s Board. Prior to joining Rustic Canyon in 2005, David worked at eBay, The Walt Disney Company, and at the White House as the Executive Assistant to the National Security Advisor, where he was awarded the Secretary of Defense’s Award for Outstanding Public Service. David currently serves on the Board of LA’s BEST Friends. David received his B.A. from Stanford University and his M.B.A. from Harvard Business School.

Gena Cook, Co-Founder and CEO

Gena has over 18 years of healthcare experience with 16 years directly in the cancer field. She was most recently VP, Sales and Marketing for McKesson. Prior to that she was the VP, Sales and Marketing for OTN and a part of the management team that spun OTN out of Bristol-Myers Squibb in 2005 and subsequently sold the company to McKesson in 2007. At OTN and McKesson, Gena was responsible for the $3.5B physician services organization that sold technology, distribution, group purchasing and financial services into oncology and rheumatology physician offices. Previously, she also held a variety of leadership positions with Bristol-Myers Squibb in her 12-year tenure. Gena received her B.A. in Business Administration from the University of Washington.

Eva Ho, Co-Founder & Advisor

Eva Ho currently serves as the Senior Executive Director of Whole Child LA and as an executive advisor for Factual, a technology start-up in Los Angeles. She was a Senior Product Marketing Manager at Google and Youtube for 5 years. Prior to Google, Eva was the head of marketing for Applied Semantics, a company that was sold to Google in 2003. Additional past employers include The Wilkerson Group, Procter & Gamble and IBM. Eva holds an MBA from the Cornell University Johnson School of Management as well as an AB in Biology from Harvard University.

Paul Zeltzer, MD, Co-Founder & Advisor

Dr. Zeltzer is a neuro-oncologist, educator, brain cancer researcher and author whose medical career spans 30 years with expertise in the areas of neuro-oncology, immunotherapy, and clinical trials against cancer. He completed training at UCLA as a specialist in Pediatric Hematology and Oncology and Tumor Immunology. Over the next 25 years, he was Associate Professor at University of Texas Health Science Center at San Antonio; Head, Brain Tumor Program, Childrens Hospital Los Angeles; Professor and Chief, Pediatric Hematology Oncology at University of California, Irvine. Most recently he was Neurooncologist at the Maxine Dunitz Neurosurgical Institute at Cedars Sinai Medical Center in Los Angeles.

Dr. Zeltzer is an advisor to five major brain tumor Foundations and web sites. He has edited two major text books in Neuro-Oncology and Oncology, authored more than 130 research publications studying molecular biology, treatment, and long term outcomes for brain tumor patients and has written two books on brain cancer, specifically for patients.

Linda D. Bosserman MD, FACP, Medical Advisory Board Member

Dr. Linda Bosserman is a medical oncologist and President of Wilshire Oncology Medical Group. She serves as co-editor to Community Oncology and is a founding board member of Cancer Clinics of Excellence, (CCE) and the Community Oncology Alliance (COA). She has also served on the Board of Directors and chaired the Breast Health Committee of the California division of the American Cancer Society (ACS) as well as on the board of directors for the San Bernardino County California Medical Society and on the Public Issues Committee of the American Society of Clinical Oncology (ASCO). Dr. Bosserman lectures and writes for lay and professional audiences with a focus on breast cancer, practice organization and electronic medical record use to facilitate quality care delivery in cancer practices. She has worked actively with COA, ACS, ASCO and CCE to bring the voice of community oncology to elected representatives, the Centers for Medicare/Medicaid Services officials, President Obama’s heath reform committee and the payer community.

Dr. Bosserman has received numerous awards distinguishing her as a leader and advocate for community cancer care and as a clinical humanitarian. Most recently she received national attention with her selection by her peers to be included in the Best Doctors database for 2006, 2007, 2008, 2009 and 2010. She actively participates in on-going clinical research trials, as principle investigator for the National Breast Cancer Prevention Trials and a founding member of the Community/UCLA Oncology/TORI Clinical Trials Network. She accepted the ASCO Clinical Trials Excellence award on behalf of Wilshire Oncology in 2009. She has focused her leadership on the development and implementation tools and techniques to enable community oncologists and oncology practices to deliver, document and quantify quality oncology care while enhancing community patient participation in clinical trials in prevention, supportive care and cancer therapy. She believes that the reporting and study of comprehensive community care serving 85% of Americans can be a foundation for physician leadership in health care reform.

Linda Bosserman, MD, FACP, received her medical degree, completed internship and residency in internal medicine and served on the faculty at Stanford University. This was followed by oncology fellowships and faculty appointments at Harvard Medical School, Dana-Faber Cancer Institute and Brigham and Women’s Hospital.

Kurt Neumann MD, FACP, Medical Advisory Board Member

Dr. Kurt Neumann is a medical oncologist who practiced in his own private practice for 30 years at Hematology Oncology Consultants in Royal Oak, Michigan. He left the practice in 2007 and has been a director and vice president at Oncology Physician Resource, a medical service and purchasing organization for physicians across the state of Michigan and beyond, and one of the founding directors of Beaumont Oncology Network, a newly formed physicians services organization affiliated with the private practice physicians who serve cancer patients and William Beaumont Hospital in Royal Oak, Michigan.

Dr. Neumann spent his career in leadership positions in the cancer community in Michigan including director and president of Michigan Society of Hematology Oncology, medical director, Hospice of Michigan, board of directors, Michigan Chapter Luekemia Society of America, board of trustees, Hospice of Southeastern Michigan, and director of oncology services, Rose Cancer Center of William Beaumont Hospital.

Dr. Neumann received his B.S. in Zoology with high distinction at the University of Michigan and his medical degree cum laude at Harvard Medical School. He completed his internship at San Francisco General Hospital and residency and fellowship at University of California, San Francisco. He also was a visiting scholar at Stanford Unversity School of Medicine.

Jack West MD, Medical Advisory Board Member

Dr. Jack West is a medical oncologist and Medical Director of the Thoracic Oncology Program at the Swedish Cancer Institute in Seattle, Washington. He also serves as President of the medical education website OncTalk, LLC and the Global Resource for Advancing Cancer Education (GRACE). Dr. West maintains a strong interest in clinical trials research in lung, prostate, and genitourinary oncology as well as a passion in helping patients understand their options and to be informed.

Dr. West received an M. Phil. in Experimental Biology from Cambridge University on a Fulbright Scholarship before returning to the US to undertake his medical training at Harvard Medical School in Boston, where he earned his MD magna cum laude and conducted research as a Howard Hughes Medical Student Fellow. He stayed in Boston for his internship and residency in internal medicine at Brigham and Women’s Hospital, then moved to Seattle, Washington for his fellowship in medical oncology at the Fred Hutchinson Cancer Research Center/University of Washington. He moved to the Swedish Cancer Institute in Seattle in late 2002, where he directs the medical oncology component of thoracic oncology program. In 2007, he was named one of the Best Doctors in Seattle by his regional medical colleagues.

Peter Grimm MD, Medical Advisory Board Member

Doctor Peter Grimm is a prostate cancer specialist and the Director of the Prostate Cancer Treatment Center in the Seattle area. Dr. Grimm received his undergraduate education at Seattle University, medical education at Midwestern University (Chicago College of Osteopathic Medicine, and his graduate training in radiation oncology at UCLA. In the late 1980’s he pioneered with his partners John Sylvester and John Blasko, a low-dose brachytherapy technique known as seed implantation for prostate cancer. Dr. Grimm, along with his colleagues, established the Seattle Prostate Institute (SPI) in 1997 and their new center the Prostate Cancer Treatment Center in July, 2009.

As CEO of Seattle Prostate Institute from 1997 to 2004, he was instrumental in forming SPIE, an educational business dedicated to training and support of brachytherapy physicians. He and his pioneering colleagues have treated over 10,000 patients and have trained over 6000 physicians from around the world in prostate brachytherapy. Over one thousand centers now perform seed implantation, which is now a treatment of choice for many men with prostate cancer.

Dr. Grimm’s technical endeavors, such as the development of six U.S. patented devices, have lead to continuous improvements in the equipment widely used in prostate implantation. He has served as one of fifteen physicians on the Medicare Practicing Physicians Advisory Board in Washington DC, is the CEO of ProQura, a medical quality assurance company, and serves on the ASTRO economic committee. He also serves on advisory boards for Nexcura, a medical advice and information company, Bard Urology, Oncura, and Watson Pharmaceuticals. As lead editor he and his partners also edited and published a collaborative book on prostate cancer, The Prostate Cancer Treatment Book, published by McGraw Hill in 2004.

Born and raised in Seattle, Dr. Grimm continues to pursue many civic activities, including his lifelong passion for preserving wild salmon. In a cooperative effort with the Hood Canal Salmon Enhancement Group and Washington State Department of Wildlife, he has released over 3 million wild salmon. He also serves as a board member for Long Live the Kings, a non-profit organization dedicated to preserving wild salmon in the Northwest. is married to Dawn Winters, PhD and has two children, Robyn Vera, DO and Justin Grimm.